SimuGen differentiates itself as a computational biology company by developing next generation drug screens that provide essential intelligence to make rapid, reliable decisions in drug discovery.

SimuGen's products and services combine best practices in traditional, genomic and high content in vitro screening, which allows drug discovery programme managers to seamlessly incorporate powerful risk assessment together with their current ADME workflows.

SimuGen covers everything from traditional hazard identification to unique risk assessment methods to address diverse customer needs. For example, its flagship analytics software explicitly models how genes are expressed with increasing toxicity over a wide spectrum of safety concerns. This means risk assessment of clinical endpoints such as fatty liver, zone 3 necrosis or carcinogenesis, within a framework of your drug safety priorities, is now possible.

By integrating in vitro gene expression and HCS data from a lead compound programme, you will not only be able to predict toxic outcomes, but also the relative doses at which these occur. Until today this crucial step has eluded drug developers worldwide. Combining this with your input on the relative priority of various toxicities, you are able to thoroughly triage and risk-assess your programme for further analysis. These activities will give you a truly data-rich decision making combination, which will quickly translate into a competitive advantage through higher pipeline productivity in the hit to lead process.

SimuGen offers comprehensive toxicology screening services (HT-X™) and high-throughput decision analytics software (HT-Stream™) for customers’ drug programmes.

For more information please check our FAQ's